Baseline characteristics of the 3096 patients recruited into the ‘Triple Antiplatelets for Reducing Dependency after Ischemic Stroke’ trial

International Journal of Stroke

Volumn 12, Issue 5, 2017, Pages 524-538

  Bath, Philip MW ^a,b   Appleton, Jason P ^a,b   Beridze, Maia ^c   Christensen, Hanne ^d   Dineen, Robert A ^a   Duley, Lelia ^a   England, Timothy J ^a   Heptinstall, Stan ^a   James, Marilyn ^a   Krishnan, Kailash ^a   Markus, Hugh S ^e   Pocock, Stuart ^f   Ranta, Annemarei ^g   Robinson, Thompson G ^h   Flaherty, Katie ^a   Scutt, Polly ^a   Venables, Graham S ⁱ   Woodhouse, Lisa J ^a   Sprigg, Nikola ^a,b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^c Hospital of War Veterans   (Georgia)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^g UNIVERSITY OF OTAGO   (New Zealand)

^h UNIVERSITY OF LEICESTER   (United Kingdom)

ⁱ ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Acute ischemic stroke; acute transient ischemic attack; aspirin; bleeding; clopidogrel; dipyridamole; randomized controlled trial

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPYRIDAMOLE; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

AGED; ARTICLE; BLEEDING; BLOOD PRESSURE; BRAIN ISCHEMIA; CAUCASIAN; COGNITION; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DEATH; DISABILITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEMALE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MOOD; MULTICENTER STUDY; NEUROIMAGING; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; RECURRENCE RISK; RECURRENT DISEASE; RISK REDUCTION; SIDE EFFECT; TRANSIENT ISCHEMIC ATTACK; TRIPLE ANTIPLATELET THERAPY; ANALOGS AND DERIVATIVES; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; MORTALITY; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

AGED; ASPIRIN; BRAIN ISCHEMIA; DIPYRIDAMOLE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; SEVERITY OF ILLNESS INDEX; STROKE; TICLOPIDINE; TREATMENT OUTCOME;

EID: 85023754091     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1177/1747493016677988     Document Type: Article

References (50)

1. Rothwell PM, Giles MF, Chandratheva A. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet Neurol 2007; 370: 1432–1442.
2. Lavallee PC, Meseguer E, Abboud H. A transient ischaemic attack clinic with round-the-clock access (SOS0TIA): feasibility and effects. Lancet Neurol 2007; 6: 953–960.
3. PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J 1995; 108: 710–717.
4. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–1041.
5. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and the secondary prevention of stroke and other vascular events: a systematic review. Stroke 2003; 34: 2741–2749.
6. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363: 757–767.
7. Rothwell PM, Eliasziw M, Gutnikov SA, Warlow CP, Barnett HJM. for the Carotid Endarterectomy Trialists Collaboration. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet 2004; 363: 915–924.
8. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549–559.
9. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after TIA or minor stroke. Lancet 1993; 342: 1255–1262.
10. Diener HC, Aichner F, Bode C. Primary and secondary prevention of cerebral ischemia Joint Guidelines of the German Society of Neurology (DGN) and German Stroke Society (DSG). Aktuel Neurol 2010; 37: E2–E22.
11. Hankey GJ, Patel MR, Stevens SR. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 2012; 11: 315–322.
12. Easton JD, Lopes RD, Bahit MC. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 2012; 11: 503–511.
13. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatr 1991; 54: 1044–1054.
14. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325: 1261–1266.
15. International Stroke Trial Collaborative Group. The International Stroke Trial (IST); a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997; 349: 1569–1581.
16. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997; 349: 1641–1649.
17. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European stroke prevention study.2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1–13.
18. Leonardi-Bee J, Bath PM, Bousser MG. Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. Stroke 2005; 36: 162–168.
19. The ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367: 1665–1673.
20. Halkes PH, Gray LJ, Bath PM. Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk. J Neurol Neurosurg Psychiatr 2008; 79: 1218–1223.
21. Bhatt DL, Fox KAA, Hacke W. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706–1717.
22. Diener HC, Bogousslavsky J, Brass LM. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331–337.
23. Bath PMW. Role of aspirin in MATCH. Lancet 2004; 364: 1662.
24. Rothwell P, Algra A, Chen Z, Diener H, Norrving B, Mehta Z. Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. Lancet 2016; 388: 365–375.
25. Geeganage CM, Diener HC, Algra A. Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials. Stroke 2012; 43: 1058–1066.
26. Wang Y, Wang Y, Zhao X. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013; 369: 11–19.
27. Wong KSL, Wang Y, Leng X. Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis. Circulation 2013; 128: 1656–1666.
28. Michelson AD, Cattaneo M, Eikelboom JW. Aspirin resistance: position paper of the working grop on aspirin resistance. J Thromb Haemost 2005; 3: 1309–1311.
29. Siller-Matula J, Schror K, Wojta J, Huber K. Thienopyridines in cardiovascular disease: Focus on clopidogrel resistance. Thromb Haemost 2007; 97: 385–393.
30. Serebruany V, Cherala G, Williams C. Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of “resistance”. Am Heart J 2009; 158: 925–932.
31. Zhao L, Bath P, Heptinstall S. Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro. Br J Pharmacol 2001; 134: 353–358.
32. Scholz T, Zhao L, Temmler U, Bath P, Heptinstall S, Losche W. The GPIIb/IIIa antagonist eptifibatide markedly potentiates platelet-leukocyte interaction and tissue factor expression following platelet activation in whole blood in vitro. Platelets 2002; 13: 401–406.
33. Zhao L, Bath PMW, Fox S. The effects of GPII-IIIa antagonists and a combination of three other antiplatelet agents on platelet-leukocyte interactions. Curr Med Res Opin 2003; 19: 178–186.
34. Zhao L, Fletcher S, Weaver C. Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke. Thromb Haemost 2005; 93: 527–534.
35. Zhao L, Gray LJ, Leonardi-Bee J, Weaver CS, Heptinstall S, Bath PM. Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke. Platelets 2006; 17: 100–104.
36. Sprigg N, Gray LJ, England T. A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility. PLoS One 2008; 3: e2852.
37. Willmot M, Zhao L, Heptinstall S, Bath PMW. Triple antiplatelet therapy for secondary prevention of recurrent ischemic stroke. J Stroke Cerebrovasc Dis 2004; 13: 138–140.
38. TARDIS Trial Investigators. Safety and eff icacy of intensive vs. guideline antiplatelet therapy in high-riskpatients with recent ischemic stroke or transient ischemic attack: rationale and design of the triple antiplatelets for reducing dependency after ischaemic stroke(TARDIS) trial (ISRCTN47823388). Int J Stroke 2015; 10: 1159–1165.
39. Bath PM, Robson K, Woodhouse LJ. Statistical analysis plan for the ‘Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial. Int J Stroke 2015; 10: 449–451.
40. Perry JJ, Sharma M, Sivilotti ML. Prospective validation of the ABCD2 score for patients in the emergency department with transient ischemic attack. Canad Med Assoc J 2011; 183: 1137–1145.
41. The ENOS Trial Investigators. Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial. Lancet 2015; 385: 617–628.
42. Weir CJ, Lees KR. Comparison of stratification and adaptive methods for treatment allocation in an acute stroke clinical trial. Stat Med 2003; 22: 705–726.
43. (NICE) NIfHaCE. Clopidogrel and modifiedrelease dipyridamole in the prevention of occlusive vascular events National Institute for Health and Clincal Excellence, 2005
44. NICE. Clopidogrel and modified release dipyridamole for the prevention of occlusive vascular events, 2010 (December 2010)
45. Lees KR, Bath PMW, Schellinger PD. Contemporary outcome measures in acute stroke research: choice of primary outcome measure. Stroke 2012; 43: 1163–1170.
46. Ali M, Bath PM, Curram J. The virtual international stroke trials archive. Stroke 2007; 38: 1905–1910.
47. Sandercock PA, Niewada M, Czlonkowska A. The international stroke trial database. Trials 2011; 12: 101.
48. Wardlaw J, Bath P, Sandercock P. The NeuroGrid stroke examplar clinical trial protocol. Int J Stroke 2007; 2: 63–69.
49. Roffe C, Navatte T, Crome P. The Stroke Oxygen Study (SO2S) – a multi-center, study to assess whether routine oxygen treatment in the first 72 hours after a stroke improves long-term outcome: study protocol for a randomized controlled trial. Trials 2014; 15: 99.
50. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991; 337: 1521–1526.